[Therapy and problems of parkinsonism].
D000328:Adult; D000368:Aged; D000547:Amantadine / Q000627:therapeutic use; D000818:Animals; D000928:Antidepressive Agents / Q000627:therapeutic use; D001058:Apomorphine / Q000627:therapeutic use; D001923:Brain Chemistry; D001933:Brain Stem / Q000378:metabolism; D004295:Dihydroxyphenylalanine / Q000009:adverse effects; D005260:Female; D006801:Humans; D007024:Hypotension, Orthostatic / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use; D010276:Parasympatholytics / Q000627:therapeutic use; D010300:Parkinson Disease / Q000209:etiology / Q000473:pathology / Q000628:therapy; D010301:Parkinson Disease, Postencephalitic / Q000628:therapy; D010302:Parkinson Disease, Secondary / Q000139:chemically induced; D011605:Psychoses, Substance-Induced / Q000209:etiology; D013238:Stereotaxic Techniques; D013566:Sympathomimetics / Q000627:therapeutic use
D000928:Antidepressive Agents; D008996:Monoamine Oxidase Inhibitors; D010276:Parasympatholytics; D013566:Sympathomimetics; D004295:Dihydroxyphenylalanine; D000547:Amantadine; D001058:Apomorphine
Zur Therapie und Problematik des Parkinson-Syndroms.